Lopaz

Quick links to important sections

Lopaz

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Lopaz

Lopaz is the trade name for a medicine containing the active substance Lansoprazole. It is classified as a potent Proton Pump Inhibitor (PPI), functioning primarily as an anti-secretory agent. Lopaz is generally designated as a prescription-only medicine (Rx) in most markets, contrasting with some lower-dose Lansoprazole formulations available over-the-counter (OTC).

Quick Facts
Active ingredient Lansoprazole
Form Delayed-release capsules, orally disintegrating tablets (ODTs)
Pharmacological class Proton Pump Inhibitor (PPI)
Common purpose Sustained reduction of gastric acid output
Origin Synthetic, substituted benzimidazole derivative

What Type of Medicine is Lopaz?

Lansoprazole, the molecule in Lopaz, belongs to the Proton Pump Inhibitor (PPI) class, a group of medications that provide profound and long-lasting control over acid levels. This classification is noted for its ability to inhibit acid compared to older H₂ blockers. The PPIs are derivatives of the heterocyclic organic molecule benzimidazole. This means the medication is structurally designed for targeted and robust acid control.

Composition, Origin, and Forms of Lansoprazole

The core compound, Lansoprazole, is a synthetic chemical entity developed for oral administration. Lopaz is typically supplied as delayed-release capsules or orally disintegrating tablets (ODTs). This specialized formulation, containing enteric-coated granules, is critical because Lansoprazole is highly sensitive to the acidic environment of the stomach and must be protected until it reaches the small intestine for systemic absorption. The ODT form, in particular, offers a differentiating feature focused on patient convenience, allowing the tablet to dissolve rapidly on the tongue without requiring water.

The General Purpose of Lopaz

The primary general purpose of taking Lopaz is to achieve a sustained reduction of gastric acid output over a 24-hour cycle. By effectively neutralizing the corrosive nature of the stomach environment, this anti-secretory action helps to mitigate the irritation and damage to the sensitive lining of the upper digestive tract. PPIs are utilized for promoting healing in ulcerative diseases and treating acid reflux. This supports the drug's role in creating an optimal environment for irritated tissues to repair themselves.

Regulatory References

  1. Lansoprazole - LiverTox - NIH
  2. NIH, StatPearls: Proton Pump Inhibitors

What side effects are possible with Lopaz?

Possible Side Effects and Safety Information

The safety profile for Lopaz (Lansoprazole) is based on official classifications derived from clinical trials and regulatory postmarketing surveillance. Adverse reactions are grouped by frequency and the physiological system affected, consistent with regulatory standards.

Frequency-Classified Adverse Reactions

The most common effects, those reported in approximately 1 to 10 out of every 100 patients, primarily involve the Gastrointestinal and Nervous Systems. These reactions include headache, dizziness, diarrhea, abdominal pain, nausea, flatulence, and constipation. Uncommon effects, reported less frequently, may include depression, arthralgia (joint pain), and myalgia (muscle pain).

Serious Adverse Reactions and Duration-Related Safety

Official documents highlight several serious, though infrequent, adverse reactions. These include severe cutaneous reactions, such as Stevens-Johnson syndrome (SJS) and Toxic Epidermal Necrolysis (TEN), and serious renal events like Acute Tubulointerstitial Nephritis (TIN). Furthermore, use is associated with a risk of Hypomagnesaemia and Clostridium difficile-associated diarrhea.

Specific safety patterns are linked to duration of use. Long-term exposure (typically one year or longer) is associated with an increased risk of bone fractures (hip, wrist, or spine) and the development of benign fundic gland polyps. Prolonged use may also lead to a Cyanocobalamin (Vitamin B12) deficiency.

Population and Safety Limitations

Regulatory labeling notes specific constraints for certain populations. Caution is advised for patients with moderate to severe hepatic dysfunction. Use is not recommended in pediatric patients less than one year of age. Additionally, symptomatic response to the medication does not exclude the presence of an underlying gastric malignancy.

Overdose and Emergency Response

Overdose and when to seek help

Official regulatory information regarding overdosage of Lansoprazole (Lopaz) indicates that clinical experience is limited. The documented profile notes that high single doses, such as those up to 600 mg in a reported case, did not result in defined adverse effects or clinical symptoms of overdose. Acute toxicity is not a dominant feature of the documented regulatory profile.


Mandatory Emergency Actions

The regulatory guidance is explicit that any suspected overdose requires immediate action. Users must seek immediate medical help or contact a Poison Control Center right away, regardless of whether symptoms are present. This mandatory response reflects the need for professional assessment and monitoring in all cases of suspected overexposure.


Management Constraints

The official prescribing information states that no specific antidote is available for Lansoprazole overdosage. Consequently, treatment is restricted to being symptomatic and supportive. Regulatory documents also clarify a significant limitation: Lansoprazole cannot be removed from circulation by haemodialysis, defining constraints on specific procedural management.

Therapeutic Uses of Lopaz

What Lopaz Treats: Main Uses and Benefits

Lopaz is commonly used to provide symptomatic relief across several therapeutic domains marked by heightened physiological activity and distress, which may contribute to easing the overall symptom burden. The medication is used for managing anxiety symptoms and is applied in contexts where temporary symptomatic assistance is needed for sleep disturbances and agitation.

The medication is relevant for supportive therapeutic benefit in conditions involving acute or disruptive neurological episodes and is applied in addressing symptoms of acute anxiety. It helps manage symptom clusters that may become intense or disruptive, such as overwhelming worry, emotional dread, and associated physical signs like muscle tension. Lopaz is also relevant for easing acute restlessness or agitation, and may be part of symptomatic management for prolonged or repeated seizures (e.g., status epilepticus).

“This medication offers symptomatic relief that may help patients cope more steadily with difficult episodes when symptoms become temporarily overwhelming.”

This supportive relief is often applied during phases of increased distress or discomfort. For instance, in clinical settings, it is commonly used to assist with maintaining functional stability before surgical or diagnostic procedures.


Symptom Focus: Relief for Acute Tension Lopaz is relevant when supportive symptom management is appropriate for conditions where symptoms may intensify temporarily, providing support that helps ease the overall symptom burden.

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Official Eligibility and Contraindications

The eligibility profile for Lopaz is strictly defined by government regulatory documents, outlining groups who must not use the medicine and those who require restricted use.

Classification Status and Specific Rule
Absolute Contraindications Prohibited for patients with hypersensitivity to the drug or its components, or those with uncontrolled angle-closure glaucoma.
Pediatric Use Not established; use is not recommended in children and adolescents under 18 years of age due to lack of sufficient safety and efficacy data.
Geriatric Use Allowed, but requires caution and monitoring due to a heightened risk of falls and potential for slower drug metabolism.
Pregnancy/Lactation Not recommended during pregnancy unless the official benefit is deemed to outweigh the risk. Breastfeeding is not recommended as the drug may be excreted in human milk.
Condition-Specific Restrictions Not recommended for patients with dementia-related psychosis due to documented increased mortality. Use in severe hepatic impairment is restricted and requires close liver function monitoring.

These official statements structure who can be safely considered for treatment with Lopaz and who must be excluded, based solely on mandatory regulatory criteria.

What should I know about interactions with other medicines?

Lopaz (Lorazepam) can have significant interactions with other substances, primarily those that also cause Central Nervous System (CNS) depression. Combining these can increase the risk of severe side effects such as profound sedation, respiratory depression, coma, and even death.

Major Drug Interactions

Opioids: The concurrent use of Lopaz with opioid medicines (e.g., codeine, morphine, oxycodone) must be carefully managed. The combination greatly increases the risk of severe drowsiness, difficulty breathing, and may be fatal. This combination should be reserved for cases where alternative treatment options are inadequate, and close monitoring by a healthcare provider is essential.

Other CNS Depressants: Caution is required when Lopaz is taken with other medications that slow brain activity. This includes sedatives, hypnotics, anxiolytics, certain antidepressants, antipsychotics, antihistamines, and general anesthetics. These combinations can intensify the sedative effects of Lopaz.

Other Notable Interactions

Interaction Type Examples Effect
Pharmaceutical Probenecid, Valproate May increase and prolong the effects of Lopaz.
Pharmaceutical Theophylline, Aminophylline May decrease the sedative effect of Lopaz.
Food and Drink Alcohol Greatly increases CNS depressant effects; must be strictly avoided.
Food and Drink Caffeine May reduce the therapeutic effectiveness of Lopaz.

It is crucial to inform your doctor about all prescription and non-prescription medications, herbal products, and supplements you are currently taking before starting Lopaz therapy.

Mechanism of Action

Irreversible Inactivation of the Proton Pump

Lopaz works by targeting the H^+/K^+-ATPase enzyme (the Proton Pump) found on the gastric parietal cells. The drug’s active metabolite forms a covalent disulfide bond with this enzyme, leading to its irreversible inactivation. This targeted molecular action effectively shuts down the final step of acid secretion, resulting in a sustained anti-secretory effect that persists until the cell synthesizes new enzyme molecules.


Acid-Activated Prodrug Conversion

Lansoprazole is classified as a prodrug, meaning it must be chemically activated to work. This activation occurs only when the molecule enters the highly acidic environment of the parietal cell's secretory canaliculi, where it is converted into the active sulfonamide metabolite. This mechanism ensures that the drug is preferentially activated and targeted toward the active, acid-secreting pumps, linking the drug's activation to the specific site of action.


Blockade of the Final Common Pathway

The Proton Pump represents the Final Common Pathway for acid secretion, regardless of the upstream physiological signals (such as gastrin or histamine) stimulating the parietal cell. By blocking this terminal point of acid export, Lopaz achieves broad inhibition of both stimulated and basal acid output. This mechanism leads directly to a sustained rise in the stomach's pH level.

Dosage and Administration Information

Lopaz, containing the active substance Lansoprazole, is designed for oral administration across its delayed-release capsule and orally disintegrating tablet (ODT) forms. The key procedural instruction involves taking the medicine before meals to ensure optimal absorption.

Dosing and Frequency

The standard adult dosing schedule for most conditions, such as ulcer healing, is 15 mg or 30 mg once daily. In cases of Pathological Hypersecretory Conditions (like Zollinger-Ellison Syndrome), initial doses may be 60 mg once daily, with total daily doses potentially reaching 180 mg administered in divided doses. Treatment duration is typically fixed, with short-term courses lasting between four and eight weeks.

Administration Requirements

It is an essential requirement that the delayed-release capsules and ODTs must not be crushed, split, or chewed. This procedural constraint protects the enteric-coated granules from stomach acid, allowing the drug to be absorbed properly in the small intestine. For patients who cannot swallow the capsule whole, the intact granules may be mixed into soft foods or specific juices.

Population-Specific Instructions: Standard dose adjustments are typically not required for older adults or patients with renal impairment. However, a dose reduction, often to 15 mg once daily, is utilized for patients with severe hepatic impairment (liver failure).

Recent Clinical Evidence

Research Evidence / Overview of Studies for Lopaz

Lopaz (Lansoprazole) was studied in research examining different types of ulcers found in the digestive tract. The research base for this application is built primarily on Randomized Controlled Trials (RCTs) and meta-analyses. The research examined outcomes related to the complete healing of these ulcers after the study period, with studies reporting how symptoms evolved in the observed populations.

Studies also explored research questions related to whether Lopaz was observed in some studies to prevent new ulcers from forming in individuals who must continuously take Non-Steroidal Anti-Inflammatory Drugs (NSAIDs). What remains uncertain is the extent of long-term data characterizing recurrence rates in the years immediately following the completion of initial treatment and maintenance.


Evidence for Managing Acid Reflux and Esophageal Damage

Lopaz was studied for its role in research exploring patient-reported symptom patterns in acid reflux. Lopaz was evaluated in short-term RCTs for conditions characterized by symptomatic Gastroesophageal Reflux Disease (GERD). These studies examined patient-reported outcomes describing perceived discomfort, such as heartburn frequency and the use of rescue medication.

Research for Erosive Esophagitis (EE), a condition where there is damage to the lining of the esophagus, explored the endoscopic healing rate of the physical damage and the rate of sustained endoscopic remission over periods extending up to a year. Findings describe patterns observed in the studies where the status of lesions was assessed after the standard treatment phase. However, long-term effects are not fully established regarding the sustained endoscopic status of the esophagus over many years.


Evidence for H. pylori Eradication and Special Populations

Lopaz was studied for its use as a component of a multi-drug combination therapy in research exploring outcomes related to the Helicobacter pylori bacteria. These RCTs examined the confirmed eradication rate of the bacteria. The research describes patterns related to confirmed eradication rates, but findings indicate that these rates may be associated with factors such as the local prevalence of antibiotic resistance.

Lopaz was studied in research examining pediatric patients (children and adolescents) with conditions characterized by GERD symptoms. Findings describe patterns observed in the studies with adolescents, but enrollment numbers for children with the most severe grades of esophageal damage were often limited, meaning subgroup findings are uncertain for these smaller populations.

Research has explored outcomes related to persistent throat symptoms (LPR), but results from high-quality trials were mixed, indicating that certainty remains low for this specific application.

Key Studies & References

  1. Effective maintenance treatment of reflux esophagitis with low-dose lansoprazole. A randomized, double-blind, placebo-controlled trial

Frequently Asked Questions (FAQ)

Common questions about Lopaz (FAQ)

Q: Is Lopaz a type of antidepressant or anxiety medication?

A: Lopaz (Lansoprazole) is classified as a potent Proton Pump Inhibitor (PPI). According to official product information, its purpose is to reduce stomach acid output, and it is not categorized as an antidepressant or anxiolytic (anxiety) medication.

Q: What is the longest time someone can safely take Lopaz?

A: Regulatory labeling advises that treatment duration should be the lowest effective dose for the shortest period necessary for the condition. Use for periods of a year or longer has been associated with an increased risk of bone fractures and Hypomagnesaemia (low magnesium levels).

Q: Does Lopaz cause weight gain, and if so, how common is it?

A: Weight changes, including both increases and decreases in appetite, have been noted in postmarketing data for the drug. While these effects are generally not among the most common, they are listed as possible less-frequent side effects.

Q: Can Lopaz affect my sleep schedule or cause insomnia?

A: Sleep-related effects are reported in official product information. Dizziness and fatigue are common side effects, and insomnia (difficulty sleeping) is also listed among the infrequent undesirable effects reported by patients.

Q: Can Lopaz cause stomach upset or digestive issues?

A: Gastrointestinal issues represent a frequent category of reported side effects. These include diarrhea, abdominal pain, nausea, and constipation, which are all noted in official product labeling.

Q: How long do the effects of Lopaz typically last after taking a dose?

A: Lopaz works by irreversibly blocking the final stage of acid production in the stomach. This mechanism is designed to provide a sustained anti-secretory effect that persists over approximately a 24-hour period, until the body synthesizes new acid-producing enzymes.

Q: Are headaches a common side effect when starting Lopaz therapy?

A: Headache is listed in official product information as one of the most common adverse reactions. It is generally classified as a nervous system effect.

Q: Can Lopaz cause changes in appetite?

A: Yes, changes in appetite, specifically both increased and decreased appetite, have been noted as less common side effects in reports collected after the drug was approved for market use.

Q: Does Lopaz affect hormone levels in the body?

A: Regulatory information notes that reduced stomach acid may lead to malabsorption and deficiency of Vitamin B12 (Cyanocobalamin) with long-term use. An expected increase in serum gastrin levels is also observed due to the acid reduction.

Q: Are there any vision-related side effects linked to Lopaz?

A: Official labeling notes that visual disturbances have been reported as a rare adverse reaction. Other postmarketing reports have noted occurrences of blurred vision.

Q: Does Lopaz affect my blood pressure?

A: While not common, rare postmarketing reports have noted the occurrence of cardiovascular events. Both hypertension (high blood pressure) and hypotension (low blood pressure) have been noted in this context.

Q: Is there a generic version of Lopaz available?

A: Yes, Lopaz is the trade name for the active ingredient Lansoprazole. This compound is widely available as a generic medication and is also used in many over-the-counter (OTC) acid-reducing products.

Q: Does Lopaz affect my ability to drive or operate machinery?

A: The official product information advises caution regarding driving or operating machinery. Side effects such as dizziness, vertigo, and visual disturbances have been reported, which may impair a person's ability to safely perform these activities.

Q: Are mood swings a possible side effect of Lopaz?

A: The drug's labeling lists depression as an uncommon side effect. Additionally, general mood or mental changes have been reported in postmarketing data, falling under the category of central nervous system effects.

Q: Can I take multivitamins while using Lopaz?

A: Because Lopaz reduces stomach acid, the absorption of some nutrients and vitamins, such as Vitamin B12, may be reduced. Iron absorption may also be affected, particularly with long-term use.

Q: What kind of research has been done on the long-term safety of Lopaz?

A: Official research and warnings highlight specific risks associated with long-term use (a year or more). These include an increased risk for bone fractures and the potential development of Fundic Gland Polyps in the stomach lining.

Q: Are there any specific foods I should avoid when taking Lopaz?

A: Regulatory documents do not list specific food groups that must be avoided. However, the official instructions require that the medicine be taken before meals for optimal effectiveness.

Q: What are the signs that Lopaz is starting to work for me?

A: Lopaz works to significantly reduce gastric acid output. Clinical information indicates that some patients may begin to experience relief from acid reflux symptoms, such as heartburn, within the first 24 hours of starting treatment.

Q: Are allergic reactions to Lopaz a common concern?

A: Allergic reactions are a serious concern, and known hypersensitivity to the drug is a formal contraindication. Severe skin reactions, such as Stevens-Johnson syndrome (SJS), are noted in official labeling as rare but serious adverse events.

Q: What kind of results can a patient realistically expect from taking Lopaz?

A: Studies and official information indicate that Lopaz is shown to be effective at reducing gastric acid. This action leads to the successful healing of ulcers and a significant reduction in the frequency and severity of symptoms associated with acid reflux disease.

Q: Are there any dietary restrictions generally advised with Lopaz?

A: There are no general dietary restrictions listed in the official documents. The primary administration rule related to food is that the medication should be taken before meals.

How should Lopaz be stored and disposed of?

How to Store and Dispose of Lopaz

Official regulatory guidelines for Lopaz (Lansoprazole) mandate strict conditions to protect the drug's stability. The medicine must be kept at controlled room temperature, typically 20 C to 25 C, and stored in the original container with the lid tightly closed. The product must be protected from excess heat, high humidity, and light.

Storage Restriction Requirement
Temperature Store below 30 C (room temperature)
Moisture/Light Protect from moisture and light
Child Safety Keep out of reach and sight of children
Stability Discard three months after opening (for bottle presentations)

Disposal must be conducted according to local regulations for pharmaceutical waste. If a drug take-back program is unavailable, follow the FDA's household disposal instructions by mixing the medicine with an unappealing substance, placing it in a sealed bag, and discarding it in the trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Lopaz found in:

A-Z Index: